Ovarian cancer patients demonstrating durable clinical benefit from neoadjuvant chemo-immunotherapy are associated with significant reductions in tumor-infiltrating CCR8+ regulatory T-cells

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.030

Junsik Park, JooHyang Lee, Yong Jae Lee, Jung-Yun Lee, Sang Wun Kim, Sunghoon Kim

引用次数: 0

查看原文本刊更多论文

卵巢癌患者从新辅助化疗免疫疗法中获得持久临床疗效，与肿瘤浸润的 CCR8+ 调节性 T 细胞显著减少有关

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy